These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22270346)

  • 1. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.
    Harigai M; Takeuchi T; Tanaka Y; Matsubara T; Yamanaka H; Miyasaka N
    Mod Rheumatol; 2012 Nov; 22(6):814-22. PubMed ID: 22270346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Kimura J; Agata N; Takeuchi T
    Arthritis Res Ther; 2017 Mar; 19(1):56. PubMed ID: 28288682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice.
    Kaneko A; Hirano Y; Fujibayashi T; Hattori Y; Terabe K; Kojima T; Ishiguro N
    Mod Rheumatol; 2013 May; 23(3):466-77. PubMed ID: 22895833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
    Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
    Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
    Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
    Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
    Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
    Ann Rheum Dis; 2015 Feb; 74(2):389-95. PubMed ID: 24288014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficiency and safety of adalimumab treatment in patients with active rheumatoid arthritis unresponsive to standard therapy: Russian national study results].
    Karateev DE; Nasonov EL; Luchikhina EL; Mazurov VI; Salikhov IG; Shmidt EI; Shostak NA
    Ter Arkh; 2012; 84(8):22-8. PubMed ID: 22994084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospective study of the efficiency and safety of adalimumab in treatment of active established rheumatoid arthritis].
    Pomirleanu C; Ancuţa C; Macovei L; Chirieac R
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):395-400. PubMed ID: 23077926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
    Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Hiramatsu K; Takeuchi T
    RMD Open; 2016; 2(1):e000189. PubMed ID: 26925252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
    Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.